UPSA and Remedee Labs Announce a Partnership to Improve the Quality of Life of Patients Suffering from Chronic Pain
UPSA innovates with Remedee Labs
Pharmaceutical company UPSA and start-up Remedee Labs signed a partnership aimed at providing healthcare professionals and their patients with a comprehensive approach to chronic pain management.
This partnership combines UPSA’s portfolio of analgesic medications (Dafalgan, Efferalgan) with the Remedee Well connected solution developed by Remedee Labs.
United by a common ambition – innovating to improve the quality of life of chronic pain patients – the Agen-based laboratory and the Grenoble-based start-up aim to deliver complementary, long-term solutions focused on patient well-being.
A Collaboration Between Two Stakeholders Committed to Innovation for Patients
UPSA, which founded the Pain Institute over 30 years ago, and Remedee Labs, a start-up created in 2016, are combining their expertise to offer a comprehensive approach to chronic pain care.
Starting in February 2023, UPSA’s medical representatives will begin introducing the Remedee Well solution to healthcare professionals, particularly general practitioners and rheumatologists.
This solution works by stimulating endorphin production through millimeter waves, offering a complementary wellness option for patients whose chronic pain significantly affects their quality of life.
A Combined Approach to Address a Major Public Health Issue
Acting through distinct mechanisms, the combination of paracetamol-based treatments (available in UPSA’s medications) with the Remedee Well solution presents a real benefit for the multidimensional management of chronic pain, encompassing both the physical and emotional aspects of suffering.
A Shared Commitment to Transform Patients’ Lives
Isabelle Van Rycke, President and CEO of the UPSA Group, stated: “At UPSA, we are delighted with this partnership with Remedee Labs, which concretely demonstrates our commitment to therapeutic innovation. Firmly focused on patient well-being, we aim to help millions of French people suffering from chronic pain improve their daily lives through the complementarity of our expertise.”
Gilles Litman, Chief Business Officer at Remedee Labs, added: “We are very pleased to enter into this partnership with UPSA, a historic and well-respected player in pain management in France. Together, we share the same ambition: to change the lives of those suffering from chronic pain. With UPSA, the Remedee Well solution will reach and benefit an even greater number of patients.”
Millimeter Wave Neuromodulation: A Breakthrough Technology
The technology developed by Remedee Labs is based on non-invasive neuromodulation using millimeter waves, delivered via a connected bracelet that stimulates endorphin production.
This innovative solution is complemented by a digital service platform, personalized support, and a multidisciplinary care approach.
Objective: Medical Device Certification
Remedee Labs aims to obtain medical device certification for its solution following ongoing clinical studies.